Biotech

All Articles

AstraZeneca blog posts information on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early take a look at the efficiency of its own in-house antibody-drug ...

iTeos- GSK's TIGIT superstar shows purposeful renovation

.After announcing a period 3 launch based upon good midstage outcomes, iTeos as well as GSK are actu...

More collaborative FDA can easily accelerate unusual ailment R&ampD: report

.The FDA should be actually much more open and collective to release a rise in commendations of rare...

Zenas, MBX, Bicara scalp to Nasdaq in scorching time for biotech IPOs

.It is actually an uncommonly occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX as w...

Atea's COVID antiviral fails to halt hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has actually stopped working yet another COVID-19 test, but the bio...

Neurocrine's proposal to save mental illness prospect falls short

.Neurocrine Biosciences' mental illness program pivot has stopped working. The biotech was actually ...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has actually created an overdue entrance to the radioligand party, spending 100 million euro...

F 2G increases $100M for 2nd attempt to receive brand new antifungal to market

.After F2G's very first try to get a brand-new lesson of antifungal to market was actually wrecked d...

Moderna targets $1.1 B in R&ampD costs cuts, drops 5 systems amid earnings pressures

.Moderna has actually sworn to cut R&ampD costs by $1.1 billion through 2027. The choice to retract ...

Sanofi's $80M bet on Key dystrophy medication finishes in stage 3 crash

.Merely 4 months after Sanofi bet $80 million in ahead of time cash on Key Therapeutics' losmapimod,...